Distributor inventory | Tablet
Voglibose 0.2 mg + Metformin Hydrochloride 500 mg (sustained/extended release) + Glimepiride 2 mg
Type 2 diabetes mellitus (when diet and exercise alone or monotherapy is inadequate); helps control post-meal and fasting blood glucose
Glimepiride (a sulfonylurea) increases insulin release from the pancreas. Metformin reduces glucose production in the liver and improves insulin sensitivity. Voglibose inhibits intestinal alpha-glucosidase enzymes, delaying carbohydrate absorption and reducing post-meal glucose spikes.
Take exactly as prescribed. Usually taken once daily with food (preferably with/after the main meal) to reduce stomach upset and risk of low sugar. Swallow SR/ER tablets whole; do not crush or chew. Monitor blood glucose regularly.
Common side effects of VOGLIX GM2 TAB may include:
Risk of hypoglycaemia (higher if meals are skipped, excessive exercise, or with alcohol/other antidiabetics); lactic acidosis risk with metformin (seek urgent care for rapid breathing, severe weakness, unusual muscle pain). Avoid/use with caution in kidney impairment, liver disease, dehydration, severe infection, or heart failure; periodic kidney function tests advised. Withhold metformin around iodinated contrast procedures and major surgery as advised by doctor. Not for type 1 diabetes or diabetic ketoacidosis.
